Breast Cancer Research and Treatment

, Volume 129, Issue 2, pp 459–465

Surgery of the primary tumor does not improve survival in stage IV breast cancer


  • Laura Dominici
    • Department of Surgical OncologyBrigham and Women’s Hospital
    • Dana Farber Cancer Institute
  • Julie Najita
    • Dana Farber Cancer Institute
  • Melissa Hughes
    • Dana Farber Cancer Institute
  • Joyce Niland
    • City of Hope Comprehensive Cancer Center
  • Paul Marcom
    • Duke University
  • Yu-ning Wong
    • Fox Chase Cancer Center
  • Bradford Carter
    • Moffitt Cancer Center
  • Sara Javid
    • University of Washington
  • Stephen Edge
    • Roswell Park Cancer Institute
  • Harold Burstein
    • Dana Farber Cancer Institute
    • Department of Surgical OncologyBrigham and Women’s Hospital
    • Dana Farber Cancer Institute
Clinical Trial

DOI: 10.1007/s10549-011-1648-2

Cite this article as:
Dominici, L., Najita, J., Hughes, M. et al. Breast Cancer Res Treat (2011) 129: 459. doi:10.1007/s10549-011-1648-2


We sought to evaluate the survival of patients who received breast surgery prior to any other breast cancer therapy following a metastatic diagnosis. Standard treatment for stage IV breast cancer is systemic therapy without resection of the primary tumor. Registry-based studies suggest that resection of the primary tumor may improve survival in stage IV cancer. We performed a retrospective analysis using data from the National Comprehensive Cancer Network (NCCN) Breast Cancer Outcomes Database. Patients were eligible if they had a metastatic breast cancer diagnosis at presentation with disease at a distant site and either received surgery prior to any systemic therapy or received systemic therapy only. Eligible patients who did not receive surgery were matched to those who received surgery based on age at diagnosis, ER, HER2, and number of metastatic sites. To determine whether estimates from the matched analysis were consistent with estimates that could be obtained without matching univariate and multivariable analyses of the unmatched sample were also conducted. There were 1,048 patients in the NCCN database diagnosed with stage IV breast cancer from 1997 to 2007. 609 metastatic breast cancer patients were identified as eligible for the study. Among the 551 patients who had data available for matching, 236 patients who did not receive surgery were matched to 54 patients who received surgery. Survival was similar between the groups with a median of 3.4 years in the nonsurgery group and 3.5 years in the surgery group. The groups were similar after adjusting for the presence of lung metastases and use of trastuzumab therapy (HR = 0.94, CI 0.83–1.08, P = 0.38). When matching for the variables associated with a survival benefit in previous studies, surgery was not shown to improve survival in the stage IV setting for this subset


Stage IV breast cancerSurgerySurvivalMastectomy

Copyright information

© Springer Science+Business Media, LLC. 2011